Uniqure Competitors
| QURE Stock | USD 21.75 1.25 6.10% |
Uniqure NV vs Abcellera Biologics Correlation
Good diversification
The correlation between Uniqure NV and ABCL is -0.04 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Uniqure NV and ABCL in the same portfolio, assuming nothing else is changed.
Moving against Uniqure Stock
| 0.81 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.72 | VERA | Vera Therapeutics | PairCorr |
| 0.71 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.64 | DXB | Dimerix Earnings Call This Week | PairCorr |
| 0.58 | DSGN | Design Therapeutics | PairCorr |
Uniqure NV Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Uniqure NV and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Uniqure and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Uniqure NV does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Uniqure Stock performing well and Uniqure NV Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Uniqure NV's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| VRDN | 1.70 | (0.02) | (0.02) | 0.01 | 2.07 | 3.71 | 10.39 | |||
| GPCR | 5.12 | 1.68 | 0.39 | (2.36) | 3.42 | 8.23 | 112.39 | |||
| EWTX | 3.82 | 0.64 | 0.14 | 0.99 | 4.35 | 11.41 | 38.85 | |||
| OCUL | 3.24 | (0.58) | 0.00 | 4.67 | 0.00 | 6.04 | 36.20 | |||
| GLPG | 0.88 | 0.02 | 0.00 | 0.08 | 1.28 | 2.21 | 6.36 | |||
| VERA | 3.23 | 0.55 | 0.20 | 0.33 | 2.60 | 8.21 | 17.87 | |||
| NUVB | 3.81 | 0.43 | 0.09 | 0.50 | 4.41 | 6.34 | 68.61 | |||
| CLDX | 2.40 | (0.10) | 0.00 | (0.05) | 0.00 | 5.63 | 14.68 | |||
| MESO | 2.76 | 0.19 | 0.04 | 2.08 | 3.44 | 7.21 | 19.08 | |||
| ABCL | 3.28 | (0.27) | 0.00 | 0.49 | 0.00 | 6.33 | 28.69 |
Cross Equities Net Income Analysis
Compare Uniqure NV and related stocks such as Viridian Therapeutics, Structure Therapeutics, and Edgewise Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VRDN | (7.2 M) | (7.2 M) | (7.2 M) | (2.2 M) | (7.9 M) | (11.3 M) | (12.7 M) | (26.5 M) | (32.7 M) | (41.9 M) | (110.7 M) | (79.4 M) | (129.9 M) | (237.7 M) | (269.9 M) | (243 M) | (230.8 M) |
| GPCR | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (40 M) | (51.3 M) | (89.6 M) | (122.5 M) | (110.3 M) | (104.8 M) |
| EWTX | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (17.1 M) | (42.1 M) | (15.4 M) | (100.2 M) | (133.8 M) | (120.4 M) | (114.4 M) |
| OCUL | (14.1 M) | (14.1 M) | (14.1 M) | (13.3 M) | (28.6 M) | (39.7 M) | (44.7 M) | (63.4 M) | (57.7 M) | (86.4 M) | (155.6 M) | (6.6 M) | (71 M) | (80.7 M) | (193.5 M) | (265.9 M) | (252.6 M) |
| GLPG | (3.6 M) | (33.1 M) | (5.7 M) | (8.1 M) | 33.2 M | (118.4 M) | 54 M | (115.7 M) | (29.3 M) | 149.8 M | (305.4 M) | (125.4 M) | (218 M) | 211.7 M | 74.1 M | 66.7 M | 70 M |
| VERA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (53.4 M) | (32.6 M) | (89.1 M) | (96 M) | (152.1 M) | (136.9 M) | (130.1 M) |
| NUVB | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (33.6 M) | (41.7 M) | (86.8 M) | (104.2 M) | (75.8 M) | (567.9 M) | (511.1 M) | (485.6 M) |
| CLDX | (1.7 M) | (44.8 M) | (59.1 M) | (81.5 M) | (118.1 M) | (127.2 M) | (128.5 M) | (93 M) | (151.2 M) | (50.9 M) | (59.8 M) | (70.5 M) | (112.3 M) | (141.4 M) | (157.9 M) | (142.1 M) | (135 M) |
| MESO | (1.5 M) | (71.1 M) | (61.7 M) | (81 M) | (119.4 M) | (4.1 M) | (76.8 M) | (35.3 M) | (89.8 M) | (77.9 M) | (98.8 M) | (91.3 M) | (81.9 M) | (88 M) | (102.1 M) | (91.9 M) | (87.3 M) |
| ABCL | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | (2.2 M) | 118.9 M | (2.2 M) | 158.5 M | (146.4 M) | (162.9 M) | (146.6 M) | (139.2 M) |
Uniqure NV and related stocks such as Viridian Therapeutics, Structure Therapeutics, and Edgewise Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Uniqure NV financial statement analysis. It represents the amount of money remaining after all of Uniqure NV operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Uniqure NV Competitive Analysis
The better you understand Uniqure NV competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Uniqure NV's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Uniqure NV's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Uniqure NV Competition Performance Charts
Five steps to successful analysis of Uniqure NV Competition
Uniqure NV's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Uniqure NV in relation to its competition. Uniqure NV's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Uniqure NV in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Uniqure NV's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Uniqure NV, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Uniqure NV position
In addition to having Uniqure NV in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alcohol Thematic Idea Now
Alcohol
Companies involved in production and distribution of wines and alcoholic beverages. The Alcohol theme has 18 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alcohol Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Uniqure NV Correlation with its peers. For information on how to trade Uniqure Stock refer to our How to Trade Uniqure Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Will Biotechnology sector continue expanding? Could Uniqure diversify its offerings? Factors like these will boost the valuation of Uniqure NV. Anticipated expansion of Uniqure directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Uniqure NV data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.18) | Earnings Share (4.40) | Revenue Per Share | Quarterly Revenue Growth 0.618 | Return On Assets |
Understanding Uniqure NV requires distinguishing between market price and book value, where the latter reflects Uniqure's accounting equity. The concept of intrinsic value - what Uniqure NV's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Uniqure NV's price substantially above or below its fundamental value.
It's important to distinguish between Uniqure NV's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Uniqure NV should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Uniqure NV's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.